miRNA Sequencing And Assay Market Size, Share & Trends Report

miRNA Sequencing And Assay Market Size, Share & Trends Analysis Report By Product & Service, By Technology, By Workflow, By Application (Cancer, Autoimmune Disease, Schizophrenia), By End-use, By Region, And Segment Forecasts, 2021 - 2028

  • Published Date: Jul, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-4-68039-394-2
  • Format: Electronic (PDF)
  • Historical Data: 2017 - 2019
  • Number of Pages: 136

Report Overview 

The global miRNA sequencing and assay market size was valued at USD 224.8 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 13.0% from 2021 to 2028. The development of technologically advanced sequence analysis platforms is expected to offer growth avenues to this market. Sequence analysis of miRNA facilitates the discovery of previously non-characterized miRNAs (microRNAs); and assists in the examination of miRNA isoforms, study disease associations as well as tissue-specific expression patterns. Sequencing of small RNAs and miRNA provides valuable insights into the assessment of their biological functions including RNA silencing and regulation of gene expression. Additionally, miRNAs are the key biomarkers of various diseases and their misregulation may lead to the development of cancer and other serious illnesses.

U.K. miRNA sequencing and assay market size, by product & service, 2017 - 2028 (USD Million) 

miRNA sequence analysis using next-generation sequencing is often preferred over microarrays as it offers a better signal-to-noise ratio and facilitates efficient sequencing. Moreover, small RNAs, such as miRNA, piRNA, siRNA, and others are involved in cellular processes such as apoptosis, differentiation, cell development, and RNA-mediated epigenetic regulation of gene expression.

Sequence analysis of small RNAs facilitates the discovery of novel miRNAs and other small RNAs and helps in the assessment of differential expression of these nucleic acids in a sample. The technique is ideal for the analysis of microRNAs without prior secondary structure or sequence information, and characterization of variations including isomiRs with single-base resolution.

Additionally, increasing applications of miRNA sequence analysis techniques have led to significant investments by key players in this market. This has resulted in the rapid development of a strong product line in the market. Most of these products are advancements to existing product lines used in biotechnology. This gave key competitors an advantage to develop and launch products faster than the new entrants.

Product & Services Insights

The product segment led the market and accounted for the largest revenue share of 80.9% in 2020 owing to the wide application of miRNA sequencing and assay in healthcare industries. Moreover, key players offer an extensive range of technologically advanced products in this segment. For instance, Illumina Inc. offers an extensive range of library preparation, sequencing instruments, accessories, consumables, and software and informatics for miRNA sequence analysis.

Moreover, ongoing extensive research to develop new products is likely to expand segment market share during the forecast period. For instance, researchers from the Université de Lyon developed BrumiR, an algorithm that can discover miRNAs exclusively and directly from sRNA-seq data. The results demonstrated by this toolkit were found to be much faster and more efficient.

The service segment is anticipated to grow at a lucrative rate in the market throughout the forecast period. Several prominent players offer services in miRNA sequencing and assay. Companies such as Eurofins Genomics, Arraystar Inc., Novogene Co., Ltd., Creative Biolabs, and others offer an extensive workflow for miRNA sequencing and assay.

Technology Insights

The Sequencing by Synthesis (SBS) technology segment dominated the microRNA sequencing and assay market and accounted for the largest revenue share of 31.8% in 2020. The large share of the segment is attributed to the ongoing research and study in miRNA sequencing and assay by synthesis. According to a January 2021 study, researchers from Germany, China, and the U.S. evaluated the standard SBS and the approaches used for this. The study established that SBS recovered more annotated miRNAs, and generated more novel miRNAs.

Additionally, SBS technology is widely used to analyze and study several cancers and to develop personalized therapies. This is expected to contribute to a large share of the segment during the forecast period. Sequencing by Oligonucleotide Ligation and Detection (SOLiD) technology is known for its accuracy particularly when the coverage is more than 30x. Hence, it is extensively used in identifying variations in resequencing, transcriptome sequencing, and targeted resequencing. At Present, systems available in the market have 99.99% accuracy and 30 G per run of data output. Therefore, the SOLiD technology segment is anticipated to witness the fastest CAGR over the forecast period.

Workflow Insights

The sequencing workflow segment dominated the microRNA sequencing and assay market and accounted for the largest revenue share of 53.3% in 2020. Small RNA sequencing is becoming a popular approach to address multiple biological issues associated with the regulation of miRNAs and other small non-coding RNAs. miRNA, piRNA, and siRNA are the three most focused small RNAs and are extensively analyzed by sequencing since they have been identified to play a crucial role in the post-translational regulation of gene expression.

Additionally, sequence analysis helps to identify and analyze a complete range of miRNA and small RNA species. Furthermore, miRNA sequencing and assay also helps identify how post-transcriptional regulation affects phenotype and discover novel biomarkers, which has broad application in complex disease and cancer research. Illumina inc. platforms are the most popular instruments for miRNA sequence analysis, such as MiSeq and HiSeq.

The library preparation segment held the second-largest revenue share in the market in 2020. Companies like GENEWIZ offer library preparation services as a standalone service to customers and accelerate their in-house capabilities. GENEWIZ offers services for sequencing of the amplicon, RNA-Seq, exome, whole-genome, targeted resequencing, and cancer panels.

Application Insights

The cancer segment dominated the market and accounted for the largest revenue share of 36.0% in 2020. Dysregulated miRNAs have been studied as a new type of tumor suppressor gene or oncomiR which are playing important roles in cancer initiation and development. Aberrant expression of miRNAs shows great potential as cancer biomarkers with high sensitivity and specificity.

miRNAs play a crucial role in the regulation of hallmarks of cancer, such as apoptosis, proliferation, invasion, metastasis, and stemness in tumors. Many miRNAs are identified as biomarkers for breast cancer for diagnosis and indicators of prognosis. Furthermore, the active participation of several global organizations, such as the National Cancer Institute, National Foundation for Cancer Research, Cancer Research Institute, and Cancer Research U.K., in cancer research is expected to positively influence the progress of this vertical over the forecast period.

The polyglutamine diseases application segment is expected to register the fastest CAGR over the forecast period. Particular expression patterns of miRNA in the brain parenchyma and circulating fluids and have been identified as potential biomarkers for prognosis and diagnosis of polyglutamine disease.

End-use Insights

The research and academic institutes segment dominated the market and accounted for the largest revenue share of 54.9% in 2020. Several academic institutes are taking initiative to accelerate research related to miRNA sequencing and assay. For instance, the University of Manchester researchers have created a database of miRNAs that have become an important resource in academia and the biotechnology industry.

Global miRNA sequencing and assay market share, by end-use, 2020 (%)

The data empowers the construction of experimental kits and resources that support experimental microRNA research across academic and industrial settings, which ultimately benefits product development, drug discovery, and clinical research. The pharmaceutical and biotechnology industry segment is expected to witness a substantial CAGR over the forecast period. Companies such as Regulus Therapeutics are involved in the development of miRNA-based therapeutics. Rising investments to develop techniques and tools to overcome existing challenges in the clinical translation of miRNA sequencing and assay applications are likely to supplement segment growth.

Regional Insights

North America dominated the miRNA sequencing and assay market and accounted for the largest revenue share of 46.1% in 2020. This can be attributed to the local presence of a significant number of key players, such as Illumina Inc., Thermo Fisher Scientific, PerkinElmer, Inc., and others. The increase in research and development spending by major players to develop innovative and advanced products in the U.S. is expected to drive regional growth. For instance, in 2020 Illumina, Inc. spent USD 682 million on research and development to develop new sequence analysis technology and upgrade existing technology.

The presence of several associations and organizations operating in this region that take initiatives to spread awareness about new advanced miRNA sequencing products and technology drive regional growth. Additionally, miRNA sequencing and assay are significantly adopted by clinics, healthcare networks, military, and agriculture laboratories that receive support through government funding. Thus, supportive government laws and investments are contributing to the regional market growth.

In Asia Pacific, the market is expected to witness the fastest growth rate over the forecast period owing to the presence of various organizations and associations that are taking initiatives to educate young scientists in this region. For instance, APBioNet is an Asia Pacific bioinformatics network is intended to track the development of the bioinformatics infrastructure, to the exchange of data and information, and to conduct training programs, workshops, and conferences.

Key Companies & Market Share Insights

Illumina, Inc. and Thermo Fisher Scientific, Inc. are the two major players in this market. Further, the extensive range of product and service portfolios offered by Illumina, Inc. has led to an increase in the company's revenue for miRNA sequencing and assay. Also, the company’s wide distribution network has significantly enhanced its market share.

Furthermore, several market players follow organic growth strategies to reinforce their market presence. In June 2020, Lexogen GmbH launched the TraPR (Trans-Kingdom, Rapid, Affordable Purification of RISCs) Small RNA Isolation Kit. The new kit offers accurate, cost-efficient, and highly reproducible analysis of sRNAs. Some of the prominent players in the miRNA sequencing and assay market include:

  • Thermo Fisher Scientific, Inc.

  • Illumina, Inc.

  • QIAGEN

  • PerkinElmer, Inc.

  • Abcam plc

  • New England Biolabs

  • Takara Bio Inc.

  • Lexogen GmbH

  • Norgen Biotek Corp

  • Maravai LifeSciences

  • HTG Molecular Diagnostics, Inc.

  • Meridian Bioscience, Inc.

  • System Biosciences, LLC

miRNA Sequencing And Assay Market Report Scope

Report Attribute

Details

Market size value in 2021

USD  253.0 million

Revenue forecast in 2028

USD  597.8 million

Growth Rate

CAGR of 13.0% from 2021 to 2028

Base year for estimation

2020

Historical period

2017 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segment coverage

Product & service, technology, workflow, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada;  Germany; U.K.; France; Spain; Italy; Japan; China; India; South Korea; Australia; Brazil; Mexico; South Africa; Saudi Arabia

Companies profiled

Thermo Fisher Scientific, Inc; Illumina, Inc.; QIAGEN; PerkinElmer, Inc.; Abcam plc; New England Biolabs; Takara Bio Inc.; Lexogen GmbH; Norgen Biotek Corp; Maravai LifeSciences; HTG Molecular Diagnostics, Inc.; Meridian Bioscience, Inc.; System Biosciences, LLC

Customization scope

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of the customization

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global miRNA sequencing and assay market report on the basis of product & service, technology, workflow, application, end-use, and region:

  • Product & Service Outlook (Revenue, USD Million, 2017 - 2028)

    • Products

      • Library Preparation Kits

      • Sequencing Consumables

      • Instruments

    • Services

  • Technology Outlook (Revenue, USD Million, 2017 - 2028)

    • Sequencing (Seq.) By Synthesis

    • Seq. By Oligonucleotide Ligation and Detection (SOLiD)

    • Nanopore Seq.

    • Sanger Seq.

    • Single Molecule Real-time (SMRT) Seq.

  • Workflow Outlook (Revenue, USD Million, 2017 - 2028)

    • Library Preparation

    • Sequencing

    • Data Analysis & Storage

  • Application Outlook (Revenue, USD Million, 2017 - 2028)

    • Cancer

    • Polyglutamine Diseases

    • Autoimmune Disease

    • Schizophrenia

    • Others

  • End-use Outlook (Revenue, USD Million, 2017 - 2028)

    • Pharmaceutical & Biotechnology Industry

    • Research and Academic Institutes

    • Contract Research Organizations

  • Regional Outlook (Revenue, USD Million, 2017 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • France

      • U.K.

      • Italy

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

      • Australia

      • South Korea

    • Latin America

      • Brazil

      • Mexico

    • Middle East Africa (MEA)

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.